Ingevity Corp (NGVT) stock
NGVTNYSEChemicals & Allied ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3073% above fair value
$61.72−0.25 (-0.40%)
Close on Nov 13, 2026Market cap $2.12BP/E 36.3Yield –
Ingevity EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Ingevity's EPS for the twelve months ending Sep 30, 2026 was $1.70. For fiscal 2025 it was -$4.61. The highest annual figure on record is $5.50 in fiscal 2022.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.61 | – |
| FY2024 | Dec 31, 2024 | -$11.85 | – |
| FY2023 | Dec 31, 2023 | -$0.15 | -102.7% |
| FY2022 | Dec 31, 2022 | $5.50 | +86.4% |
| FY2021 | Dec 31, 2021 | $2.95 | -32.5% |
| FY2020 | Dec 31, 2020 | $4.37 | +0.5% |
| FY2019 | Dec 31, 2019 | $4.35 | +9.6% |
| FY2018 | Dec 31, 2018 | $3.97 | +33.7% |
| FY2017 | Dec 31, 2017 | $2.97 | +257.8% |
| FY2016 | Dec 31, 2016 | $0.83 | -56.1% |
| FY2015 | Dec 31, 2015 | $1.89 | -38.2% |
| FY2014 | Dec 31, 2014 | $3.06 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.41 | +19.5% |
| Q2 FY2026 | Jun 30, 2026 | $1.00 | – |
| Q1 FY2026 | Mar 31, 2026 | $1.66 | +196.4% |
| Q4 FY2025 | Dec 31, 2025 | -$2.37 | -615.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.18 | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.02 | – |
| Q1 FY2025 | Mar 31, 2025 | $0.56 | – |
| Q4 FY2024 | Dec 31, 2024 | $0.46 | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.94 | -526.1% |
| Q2 FY2024 | Jun 30, 2024 | -$7.81 | -905.2% |
| Q1 FY2024 | Mar 31, 2024 | -$1.54 | -214.1% |
| Q4 FY2023 | Dec 31, 2023 | -$3.21 | -882.9% |
| Q3 FY2023 | Sep 30, 2023 | $0.69 | -65.2% |
| Q2 FY2023 | Jun 30, 2023 | $0.97 | -37.0% |
| Q1 FY2023 | Mar 31, 2023 | $1.35 | -12.9% |
| Q4 FY2022 | Dec 31, 2022 | $0.41 | -44.6% |
| Q3 FY2022 | Sep 30, 2022 | $1.98 | – |
| Q2 FY2022 | Jun 30, 2022 | $1.54 | +40.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.55 | +29.2% |
| Q4 FY2021 | Dec 31, 2021 | $0.74 | -33.3% |
| Q3 FY2021 | Sep 30, 2021 | -$0.11 | -106.5% |
| Q2 FY2021 | Jun 30, 2021 | $1.10 | +124.5% |
| Q1 FY2021 | Mar 31, 2021 | $1.20 | +11.1% |
| Q4 FY2020 | Dec 31, 2020 | $1.11 | +5.7% |
| Q3 FY2020 | Sep 30, 2020 | $1.69 | +19.9% |
| Q2 FY2020 | Jun 30, 2020 | $0.49 | -63.4% |
| Q1 FY2020 | Mar 31, 2020 | $1.08 | +100.0% |
| Q4 FY2019 | Dec 31, 2019 | $1.05 | +6.1% |
| Q3 FY2019 | Sep 30, 2019 | $1.41 | +21.6% |
| Q2 FY2019 | Jun 30, 2019 | $1.34 | +21.8% |
| Q1 FY2019 | Mar 31, 2019 | $0.54 | -25.0% |
| Q4 FY2018 | Dec 31, 2018 | $0.99 | +2.1% |
| Q3 FY2018 | Sep 30, 2018 | $1.16 | +46.8% |
| Q2 FY2018 | Jun 30, 2018 | $1.10 | +44.7% |
| Q1 FY2018 | Mar 31, 2018 | $0.72 | +60.0% |
| Q4 FY2017 | Dec 31, 2017 | $0.97 | +340.9% |
| Q3 FY2017 | Sep 30, 2017 | $0.79 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.76 | – |
| Q1 FY2017 | Mar 31, 2017 | $0.45 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.22 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?